Immunic (NASDAQ:IMUX) Stock Rating Lowered by StockNews.com

Immunic (NASDAQ:IMUX) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Thursday.

Other analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Immunic in a research note on Friday, February 21st. D. Boral Capital reissued a “buy” rating and set a $17.00 price objective on shares of Immunic in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Immunic currently has an average rating of “Buy” and an average target price of $12.67.

Immunic Stock Performance

Shares of IMUX stock opened at $1.15 on Thursday. The firm has a market capitalization of $103.59 million, a price-to-earnings ratio of -0.93 and a beta of 1.89. Immunic has a one year low of $0.92 and a one year high of $2.11. The company has a 50 day moving average price of $1.06 and a 200 day moving average price of $1.22.

Institutional Trading of Immunic

A number of institutional investors have recently added to or reduced their stakes in IMUX. Invesco Ltd. purchased a new stake in Immunic during the 4th quarter worth $37,000. Virtu Financial LLC purchased a new stake in Immunic during the 3rd quarter worth $50,000. HB Wealth Management LLC purchased a new stake in Immunic during the 4th quarter worth $81,000. Barclays PLC purchased a new stake in Immunic during the 4th quarter worth $84,000. Finally, Jane Street Group LLC boosted its position in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.